Benefits
Superior GI Tolerability
Iron bisglycinate causes substantially fewer GI side effects than ferrous sulfate — less constipation, nausea, and gastric pain. Rate of patients quitting therapy is much lower. Critical advantage for chronic supplementation, pregnancy, and IBD populations.
Better Absorption Than Sulfate
Some research suggests ferrous bisglycinate is up to 4× more bioavailable than ferrous sulfate; meta-analysis (Pineda 2018) showed iron bisglycinate more effective than other salts for raising hemoglobin in pregnant women.
Resistance to Absorption Inhibitors
The chelate structure protects iron from common absorption inhibitors — phytates (in cereals/grains), oxalates (in spinach), polyphenols (in coffee/tea). Means more reliable absorption when taken with meals.
Pregnancy Iron Supplementation
Pregnancy iron requirements increase substantially (RDA 27 mg/day vs 18 mg pre-pregnancy). Ferrous bisglycinate's tolerability is particularly valuable when nausea/morning sickness already strain GI comfort.
IBD/Crohn's/Ulcerative Colitis
Inflammatory bowel disease patients often have iron deficiency but cannot tolerate ferrous sulfate (worsens GI symptoms, may aggravate inflammation). Bisglycinate is gentler alternative for these populations.
Mechanism of action
Glycine Chelate Stability
Iron ion bonded to two glycine molecules in stable chelate. Resists gastric pH changes and competing absorption inhibitors. Absorbed via standard iron transport (DMT1) AND potentially via dipeptide transporters as an intact glycine complex.
Reduced Free Iron in GI Tract
Free Fe²⁺ in GI tract generates reactive oxygen species that damage mucosal cells — basis for ferrous sulfate's GI symptoms. Chelated bisglycinate keeps iron bound through transit, reducing free-iron-mediated mucosal damage.
Bypass of Absorption Inhibitors
Phytates and polyphenols bind free iron and reduce absorption — but cannot displace iron from the bisglycinate chelate. Iron arrives at duodenal absorption sites still bound and intact.
Standard Iron Functions
Once absorbed, iron functions identically regardless of supplemental form — incorporated into hemoglobin (oxygen transport), myoglobin (muscle oxygen storage), cytochromes (electron transport), iron-sulfur cluster enzymes.
Clinical trials
Meta-analysis comparing iron bisglycinate vs other iron salts for IDA treatment in pregnant women.
Pooled across pregnancy IDA RCTs.
Iron bisglycinate was significantly MORE effective than other iron salts (sulfate, fumarate) at raising hemoglobin in pregnant women, with SIGNIFICANTLY FEWER GI side effects. Important comparative evidence supporting bisglycinate as preferred form for pregnancy IDA.
Multiple RCTs comparing ferrous bisglycinate vs ferrous sulfate for tolerability and adherence in IDA patients.
Pooled across tolerability trials.
Ferrous bisglycinate causes substantially fewer GI side effects (constipation, nausea, abdominal pain) vs ferrous sulfate. Adherence rates higher. Supports bisglycinate as preferred form for tolerability-sensitive populations.
About this ingredient
Ferrous bisglycinate is iron CHELATED with two glycine amino acid molecules — a newer form with superior GI tolerability and good bioavailability vs ferrous sulfate. Elemental iron content: ~20% by weight (similar to sulfate).
KEY EVIDENCE: Pineda 2018 meta-analysis in pregnant women showed bisglycinate MORE EFFECTIVE for raising hemoglobin AND with FEWER side effects than other iron salts. Multiple tolerability RCTs confirm substantially better adherence vs ferrous sulfate.
EVIDENCE-BASED USES: (1) IRON DEFICIENCY ANEMIA when ferrous sulfate not tolerated; (2) PREGNANCY IDA — emerging preferred form; (3) IBD/Crohn's/UC iron supplementation; (4) Long-term iron supplementation for chronic iron loss (heavy menses, GI bleeding); (5) Pediatric iron deficiency (better-tolerated than sulfate). UNIQUE ADVANTAGES: (1) Substantially fewer GI side effects vs sulfate; (2) Resistant to phytate/polyphenol absorption inhibitors — more reliable absorption with meals; (3) Less generation of reactive oxygen species in GI tract — reduced mucosal irritation; (4) Higher patient adherence translates to better real-world clinical outcomes.
CRITICAL CAUTIONS: (1) HEMOCHROMATOSIS / iron overload — AVOID; iron supplementation contraindicated; (2) PEDIATRIC IRON POISONING — same risk as all iron supplements; child-resistant packaging mandatory; (3) DRUG INTERACTIONS — same general iron interactions (tetracyclines, quinolones, levothyroxine, bisphosphonates, levodopa, calcium); separate by 2-4 hours; chelation protection reduces but does not eliminate; (4) HEMOGLOBINOPATHIES (thalassemia minor) — consult hematology before iron supplementation; (5) FUNCTIONAL IRON DEFICIENCY in chronic disease — oral iron may not be effective regardless of form; IV iron may be needed; (6) COST — ferrous bisglycinate typically more expensive than sulfate; cost-benefit favors bisglycinate when tolerability matters; (7) PREGNANCY — Pineda 2018 supports bisglycinate as evidence-based choice.